Ovarian cancer

Ovarian cancer is the seventh most common form of cancer among women, and in the seven largest markets worldwide (the United States, the five largest countries in Europe, and Japan) alone, there are over 65,000 new cases of ovarian cancer each year.

Because the disease is difficult to detect, most cases of ovarian cancer are diagnosed at a late stage; approximately 65% of diagnosed cases are in stages III–IV. At the time of diagnosis in stages III–IV, the five-year survival rate is approximately 30 percent.

First-line standard treatment is based on surgery, followed by chemotherapy, such as platinum-based agents. Chemotherapy aims to damage the DNA of cancer cells, thereby reducing or slowing the growth of the tumor. One of the biggest obstacles to effective treatment of ovarian cancer, however, is that cancer cells develop the ability to repair the DNA damage caused by chemotherapy, thereby developing resistance to the treatment: approximately 70% of all patients experience a relapse within three years.

In the event of a relapse, the subsequent treatment regimen is determined based on the assessed severity of platinum resistance. If the patient is still deemed susceptible to platinum-based treatment, it is usually tried again. Combination therapies are most often initiated. If the patient is deemed platinum-resistant, other treatments are initiated. With each relapse, the likelihood that the next treatment will be effective decreases; consequently, there is a significant medical need to increase responsiveness to platinum-based chemotherapy, which is the goal of treatment with rugocrixan.
Although competition in this field is intense, Novakand believes that rugocrixan has a clear position in second- and third-line treatment for patients who are still considered responsive to platinum therapy.